UNSPSC 51293503: Pirandamine hydrochloride

This classification denotes an antidepressant agent with the molecular formula C17H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y4F9MIF6M1, chemically known as ay-23,713 but more generally known as pirandamine hydrochloride, which bears US NIH Compound Identifier 431429. Most nations, for tariff and trade purposes, schedule pirandamine hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, PIRANDAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Pirandamine hydrochloride bears US NLM identifiers UMLS ID C0088224 and NCI Concept Code C66411. SMILES: CC1(C2=C(CCO1)C3CCCCC3C2)CCN(C)C.CL.

UNSPSC 51293503 Pirandamine hydrochloride, a Commodity code, captures state and local procurement of pharmaceutical products — though recent opportunities tagged under this code show divergence from the nominal scope, with actual solicitations covering naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products rather than pirandamine specifically. State and local buyers under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Work solicited includes annual purchases of pharmaceutical inventory for community health initiatives and state employee benefit programs, with vendors expected to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and insurance requirements including workers' compensation and liability coverage. Contracts typically run two years with renewal options, and vendors must demonstrate capability to distribute through authorized wholesalers and maintain electronic data interchange systems for ordering and fulfillment.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for a Therapeutic Pharmacy Initiative, with no formal competition timeline. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and awards effective July 1, 2026; evaluation emphasizes price competitiveness (75 percent) and compliance with cGMP and DSCSA standards.